1548043-33-9

Upstream product

• 92093-23-7 (R)-(-)-1-(4-bromophenyl)-1,2-ethanediol 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 1548043-27-1 (R)-ethyl 2-[1-(4-bromophenyl)-2-(methoxymethoxy)ethoxy]acetate 
• 1548043-70-4 (R)-1-(4-bromophenyl)-2-(methoxymethoxy)ethanol 

Downstream Products

• 1548043-46-4 (R)-2-[1-(4-bromophenyl)-2-hydroxyethoxy]-N-hydroxyacetamide 
• 1548042-87-0 (S)-N-hydroxy-2-(2-hydroxy-1-{4-[(trimethylsilyl)ethynyl]phenyl}ethoxy)acetamide 
• 1548043-66-8 (R)-5-(4-ethynylphenyl)-1,4-dioxan-2-one 
• 1548043-67-9 (R)-2-[1-(4-ethynylphenyl)-2-hydroxyethoxy]-N-hydroxyacetamide 
• 1548043-68-0 (R)-5-(4-{[4-(morpholinomethyl)phenyl]ethynyl}phenyl)-1,4-dioxan-2-one 
• 1548043-69-1 (R)-N-hydroxy-2-[2-hydroxy-1-(4-{[4-(morpholinomethyl)phenyl]ethynyl}phenyl)ethoxy]acetamide 
• 1548043-49-7 (R)-5-[4-(phenylethynyl)phenyl]-1,4-dioxan-2-one 
• 1548043-59-9 (R)-5-{4-[(trimethylsilyl)ethynyl]phenyl}-1,4-dioxan-2-one 

Relevant academic research and scientific papers

Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors

The inhibition of the UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase (LpxC) represents a promising strategy to combat infections caused by multidrug-resistant Gram-negative bacteria In order to elucidate the functional groups being impor